Tardif JC, Kouz S, Waters DD, et al. - In this randomized, double-blind trial involving people enrolled within 30 days following a myocardial infarction, experts randomized people to receive either low-dose colchicine (0.5 mg once daily) or placebo in order to ascertain the safety and efficiency of low-dose colchicine following myocardial infarction. A total of 4,745 persons were recruited (the colchicine group, n = 2,366 and the placebo group, n = 2,379). Diarrhea was noted in 9.7% of the cases in the colchicine group and in 8.9% in the placebo group. Pneumonia was recorded as a serious adverse event in 0.9% of the individuals in the colchicine group and in 0.4% of those in the placebo group. Thus, among people with a current myocardial infarction, colchicine at a dose of 0.5 mg daily resulted in a notably lower risk of ischemic cardiovascular events compared with placebo.